5,283 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by New York State Teachers Retirement System

New York State Teachers Retirement System purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,283 shares of the biopharmaceutical company's stock, valued at approximately $1,453,000.

Several other institutional investors also recently modified their holdings of the business. Allspring Global Investments Holdings LLC boosted its position in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 143 shares during the last quarter. Janney Montgomery Scott LLC grew its position in Alnylam Pharmaceuticals by 47.4% during the first quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company's stock valued at $415,000 after buying an additional 892 shares during the period. Empowered Funds LLC grew its position in Alnylam Pharmaceuticals by 3.9% during the first quarter. Empowered Funds LLC now owns 13,849 shares of the biopharmaceutical company's stock valued at $2,070,000 after buying an additional 524 shares during the period. Illinois Municipal Retirement Fund purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at approximately $3,942,000. Finally, Forsta AP Fonden raised its position in Alnylam Pharmaceuticals by 199.6% in the first quarter. Forsta AP Fonden now owns 68,300 shares of the biopharmaceutical company's stock worth $10,207,000 after acquiring an additional 45,500 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ALNY. Canaccord Genuity Group boosted their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research report on Friday, November 1st. TD Cowen increased their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a research note on Monday, October 21st. JPMorgan Chase & Co. raised their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research report on Monday, August 26th. Royal Bank of Canada restated an "outperform" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the company from $198.00 to $370.00 in a report on Friday, August 16th. Six investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $294.50.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded up $5.21 during mid-day trading on Friday, reaching $277.43. 848,533 shares of the company traded hands, compared to its average volume of 925,552. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm has a market cap of $35.78 billion, a PE ratio of -105.89 and a beta of 0.39. The stock has a fifty day simple moving average of $274.17 and a 200-day simple moving average of $230.84. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the business posted $1.15 earnings per share. The firm's revenue for the quarter was down 33.3% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.